Skip to main content
RLAY
NASDAQ Life Sciences

Relay Posts $848.6M Cash, Accelerates Breast Cancer Enrollment to Mid-2027

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$18.02
Mkt Cap
$3.951B
52W Low
$5.95
52W High
$21.27
52W Position info
203% above low
Off High info
15% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

RLAY has more than doubled off its 52-week low of $5.95.

Summary

Relay ended Q3 with $848.6 million in cash, cash equivalents and investments, down from $910.9 million at June 30, and says that funds operations into 2029. The quarter's net loss widened to $81.7 million, or $0.37 per share, from $74.1 million a year earlier, as R&D rose to $77.1 million on trial costs and lease termination charges. The key pipeline update: Phase 3 ReDiscover-2 in second-line PI3Kα-mutated breast cancer is now expected to complete enrollment in mid-2027, roughly a year faster than recent benchmarks. Relay also hired Shannon Campbell, most recently CCO at Merus, as Head of Commercial, and disclosed a new late-preclinical mutant-selective TIE2 inhibitor program for vascular malformations. Updated zovegalisib vascular anomalies data plus a regulatory update are set for an ASH oral presentation on December 14, 2026, with a company call that day; a regulatory update confirming the Phase 3 design in first-line endocrine-sensitive breast cancer is expected by year-end 2026.

At the time of this announcement, RLAY was trading at $18.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4B. The 52-week trading range was $5.95 to $21.27. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

RLAY - Latest Insights

RLAY
Nov 04, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.02
Real-time Price: $16.19 info
Change: -$1.83 (-10%) info
Market Cap: $3.562B info
RLAY
Sep 22, 2026, 11:23 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $18.54
Real-time Price: $16.19 info
Change: -$2.35 (-13%) info
Market Cap: $3.562B info
RLAY
Aug 25, 2026, 7:43 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $19.88
Real-time Price: $16.19 info
Change: -$3.69 (-19%) info
Market Cap: $3.562B info
RLAY
Aug 06, 2026, 4:41 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $19.30
Real-time Price: $16.19 info
Change: -$3.11 (-16%) info
Market Cap: $3.562B info
RLAY
Aug 06, 2026, 4:40 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $19.04
Real-time Price: $16.19 info
Change: -$2.85 (-15%) info
Market Cap: $3.562B info